Tricyclic Compounds Inhibiting IKK Enzyme Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory and immune-related disorders and cancer often have limitations such as side effects, low bioavailability, and variable patient responses, with a need for more effective compounds that target the IKK enzyme pathway to modulate chemokine activity.
Innovation Solution
Development of novel tricyclic compounds that inhibit IKK enzyme activity, including specific heterocyclic systems and their pharmaceutically acceptable salts or prodrugs, for use in pharmaceutical compositions to treat conditions like rheumatoid arthritis, asthma, inflammatory bowel disease, and cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments for inflammatory and immune-related disorders are used, then therapeutic effects are achieved, but side effects occur and bioavailability is limited
Solution Approach 1:
The patent employs parameter changes by developing novel tricyclic compounds with specific molecular structures (formula I) that modify the chemical parameters of IKK inhibitors. These structural variations optimize the balance between therapeutic efficacy and reduced side effects, addressing the contradiction between reliable therapeutic effect and harmful side effects of existing treatments
Solution Approach 2:
The invention uses composite molecular structures combining multiple heterocyclic rings (imidazo, thiazolo, and pyridine moieties) in a tricyclic framework. This composite structural approach creates compounds with improved pharmacological properties, achieving better therapeutic profiles with potentially reduced side effects compared to single-structure inhibitors
2Reliability
If existing treatments are administered, then disease symptoms are addressed, but bioavailability remains low
Solution Approach 1:
The patent applies parameter changes by systematically varying molecular parameters such as substituent groups (R1-R6), ring structures, and stereochemistry in the tricyclic compounds. These parameter optimizations are designed to improve pharmacokinetic properties including bioavailability, while maintaining or enhancing therapeutic efficacy against inflammatory and immune disorders
3Reliability
If current IKK inhibitors are used, then NF-κB activation is inhibited, but patient responses vary significantly
Solution Approach 1:
The patent achieves universality by designing tricyclic compounds that can inhibit multiple IKK isoforms (IKK-α and IKK-β) with broad substrate specificity. This multi-functional inhibition approach aims to provide consistent therapeutic responses across diverse patient populations by targeting the conserved NF-κB activation pathway regardless of individual variations in disease presentation or genetic background
Data Source
AI summary
The present invention provides for thiazolopyridine-based tricyclic compounds having the formula (I),wherein R1, R2, R5 and R6 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.